Related Experiment Video
Updated: Jun 3, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
[ST-elevation myocardial infarction: reperfusion strategy based on the results from large clinical trials]
Luigi Inglese1, Cecilia Fantoni
1Divisione di Radiologia Interventistica Cardiovascolare, IRCCS Policlinico San Donato, San Donato Milanese (MI). luigi.inglese@tin.it
Insights
Timely reperfusion therapy for ST-elevation myocardial infarction (STEMI) significantly improves outcomes. Early intervention, whether pharmacological or mechanical, maximizes benefits for patient survival and quality of life.
Area of Science:
- Cardiology
- Emergency Medicine
Background:
- ST-elevation myocardial infarction (STEMI) is a critical cardiovascular event.
- Reperfusion therapy is key to managing STEMI, but its effectiveness is time-sensitive.
Purpose of the Study:
- To review the time-dependent efficacy of reperfusion strategies in STEMI.
- To discuss current guidelines and real-world challenges in STEMI management.
Main Methods:
- Review of clinical guidelines and major trials on STEMI reperfusion.
- Analysis of time-dependent benefits for pharmacological and mechanical interventions.
Main Results:
- Reperfusion therapy efficacy is highest when administered early after symptom onset.
- Pharmacological therapy is effective within 6 hours; primary angioplasty up to 12 hours.
- Real-world STEMI mortality remains higher than trial data suggests.
Conclusions:
- Early reperfusion is crucial for myocardial salvage, ventricular function, and long-term survival in STEMI patients.
- Urgent guideline implementation and revision are needed to address the gap between trial results and real-world outcomes.
Abstract:
The efficacy of reperfusion therapy, both pharmacological and mechanical, in patients with ST-elevation myocardial infarction (STEMI) is time-dependent. The relation is closer the earlier we are from symptom onset and is valid for thrombolysis within 6h and for primary angioplasty till to at least the twelfth hour. Benefits of reperfusion bring to an advantage both in terms of myocardial salvage and left ventricular systolic function and in terms of quality of life and long-term survival. Although mortality and morbidity of STEMI patients have been greatly reduced in the last 20 years, the need for guideline revision and implementation remains urgent, mostly because mortality of real-world STEMI patients keeps to be always much higher compared to what reported in big randomized controlled trials. The most important indications from big trials and guidelines regarding both pharmacological and non-pharmacological reperfusion strategy in STEMI patients are discussed.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
